Tangramed Biotech

Tangramed Biotech is a clinical-stage biopharmaceutical company dedicated to developing innovative multi-specific antibodies for the treatment of autoimmune diseases and cancer. The company utilizes its proprietary T-cell engager platform to create therapies that precisely redirect T-cells to eliminate disease-causing cells while minimizing off-target effects. Its lead candidate, TG-103, is a first-in-class trispecific antibody targeting CD3, CD19, and CD20, currently in Phase 1 clinical trials for systemic lupus erythematosus and B-cell malignancies. Founded by industry veterans with extensive experience in antibody engineering, Tangramed aims to redefine the standard of care for B-cell mediated pathologies. The company is backed by prominent venture capital firms and maintains research and development facilities in Shanghai.